UK Community Advisory Board (UK-CAB)

UK-CAB 51: Mental health and HIV

Friday 4 July 2014

Draft Programme

09.30-09.45 Registration, refreshments and expenses
09.45-10.00 Welcome, introductions, UKCAB updates
10.00-10.30 Setting standards in providing psychological support to people living with HIV: Engaging service users in the community – Dr Poul Rohleder, Anglia Ruskin University
10.30-11.00 Patient experience on mental health and HIV  – Jo Josh
11.00-11.15 BREAK
11.15-12.00 In Treatment:  improving psychological wellbeing in the HIV clinic – Dr Jenny Petrak, Homerton Hospital
12.00-12.30 States of Mind: Improving mental wellbeing in the HIV community – Silvia Petretti
12.30-14.00 Lunch
14.00-15.00 Consultation on dolutegravir policy – Damian Kelly to lead discussion
15.00-15.45 London therapeutic tender implementation discussion – Mark Platt to lead
15.45-16.00 BREAK
16.00-16.30 NIHR study to assess low dose efavirenz – Dr Alan Winston, St Mary’s Hospital
16.30-16.45 Member feedback, UK-CAB AOB
16.45 Meeting close

Presentations from this meeting

Setting the standards in providing HIV psychological support – engaging service users
Dr Poul Rohleder, 04/07/2014  [PDF, 6.3Mb]
Patient experience on mental health and HIV
Jo Josh, 04/07/2014  [PDF, 259Kb]
In Treatment: improving psychological wellbeing in the HIV clinic
Dr Jenny Petrak, 04/07/2014  [PDF, 1Mb]
NIHR study to assess low dose efavirenz
Dr Alan Winston, 04/07/2014  [PDF, 222Kb]
States of Mind: Improving mental health in the HIV community
Silvia Petretti, 04/07/2014  [PDF, 2.5Mb]

Background reading

Morning sessions:

Psychological support for adults living with HIV (short version 10 pages).

These are the first standards on psychological support published in the UK. Despite significant medical advances in HIV treatment, people living with HIV experience significantly higher rates of psychological difficulties than the general population. The standards focus on the promotion of mental health and wellbeing for all adults living with HIV, as well as the early detection of psychological difficulties and the provision of appropriate interventions for those who need them.

Full version on BHIVA website:

HIV and your quality of life
This is the section in the i-Base guide on mental health.

This is a factsheet from NAM on mental health covering HIV-related mental disorders, emotional distress, depression, mental health problems as a treatment side-effect, anxiety, psychological treatments and where to go for help and support

States of Mind: Improving mental wellbeing in the HIV community
This report, based on a survey of nearly 200 people living with HIV demonstrates the impact of mental health for people living with HIV socially and in managing their medication and highlights the lack of effective support. It concludes with recommendations to improve support and resources for people living with HIV to better manage emotional wellbeing.


Afternoon sessions:

***Consultation on dolutegravir policy ***
NHS England has launched a three-month public consultation till 17 September 2014, on changes made to a number of its specialized services policies. These policies have already been subject to stakeholder engagement and comment, however, we are now have to do them again. This is consulting on the final documents. The questions are as follows:

  • In your view, what would be the effect of the proposed changes on the service?
  • What further changes, if any do you think need to be made to this document?
  • Are there any other considerations not reflected in the document that you wish to draw our attention to?

London therapeutic tender implementation discussion
See article from HIV i-Base: New ARV prescribing guidelines for London (2014)

NIHR study to assess low dose efavirenz

Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects
Results from the ENCORE1 study comparing efavirenz at a reduced compared to standard dose in treatment naive patients.

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.